--- title: "NHS Branded Medicines Tranche Framework for London and South of England" ocid: "ocds-h6vhtk-0445bc" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0445bc" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-0445bc.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-0445bc.json" source: "Find A Tender Service" current_stage: "Award" buyer: "NHS ENGLAND" published: "2024-08-20" --- # NHS Branded Medicines Tranche Framework for London and South of England Buyer: NHS ENGLAND Current stage: Award OCID: ocds-h6vhtk-0445bc [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0445bc) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-0445bc.json) ## Summary NHS England has launched the "NHS Branded Medicines Tranche Framework for London and South of England," focusing on procuring pharmaceutical products. The procurement process is currently in the active tender stage, with an open procedure method. The framework comprises three lots, with key periods beginning on 1 September 2024, and options to extend up to 24 months at the authority's discretion. The total estimated value is £832,292,000, divided across multiple lots. The procurement falls under the goods category and targets delivery regions across England, including London, the South of England, the Midlands, and the North of England. The submission deadline for bids is 5 April 2024. Businesses in the pharmaceutical industry have significant opportunities to expand by participating in this framework. The framework offers long-term supply potential to major NHS bodies, fostering stability and continuous growth. With an open procedure, a large number of suppliers can participate, making it suitable for both large enterprises like GlaxoSmithKline UK Limited and SMEs such as Manx Healthcare Ltd. Companies specialising in branded medicines and pharmaceuticals will find this framework particularly advantageous, allowing them to enhance their market presence while contributing to healthcare services. ## Notice NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. ### Lot Information CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2 CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3 CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/026491-2024 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large, SME | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 20 Aug 2024 | | Submission deadline | 5 Apr 2024 | | Future notice date | Not specified | | Award date | 21 Jul 2024 | | Contract period | 31 Aug 2024 - 31 Aug 2025 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £832,292,000 | | Lots value | £832,293,000 | | Awards value | Not specified | | Contracts value | £1 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Cancelled | | Awards status | Active | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Locality | LEEDS | | Post town | Leeds | | Postcode | LS2 7UE | | Country | England | | ITL 1 | TLE Yorkshire and The Humber | | ITL 2 | TLE4 West Yorkshire | | ITL 3 | TLE42 Leeds | | Local authority | Leeds | | Electoral ward | Hunslet & Riverside | | Westminster constituency | Leeds South | | Delivery location | Not specified | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 30 | | Supplier names | ACCORD-UK; ASTRAZENECA; AVENTIS PHARMA LTD T/A SANOFI; AVENTIS PHARMA T/A SANOFI; BIOGEN; BIOSIMILAR COLLABORATIONS IRELAND; CELLTRION HEALTHCARE UNITED KINGDOM; CHUGAI PHARMA; DR.REDDY'S LABORATORIES (UK; ELI LILLY; GALAPAGOS BIOTECH; GEDEON RICHTER; GLAXOSMITHKLINE; JANSSEN-CILAG; LEO PHARMA; MANX HEALTHCARE; MERCK SHARPE AND DOHME (UK; NAPP PHARMACEUTICALS; NOVARTIS PHARMACEUTICALS; ORGANON PHARMACEUTICALS; ORIFARM; PFIZER; ROCHE PRODUCTS; SOBI (SWEDISH ORPHAN BIOVITRUM; SUN PHARMA; TAKEDA; TEVA; THORNTON AND ROSS; UCB PHARMA LTD (PRIMARY; ZENTIVA PHARMA | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 20 Aug 2024 at 13:23 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/026491-2024 - 5 Mar 2024 at 15:51 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/007069-2024 ## Notice URLs - http://health.atamis.co.uk - http://www.accord-healthcare.co.uk - http://www.novartis.co.uk - https://health-family.force.com/s/Welcome - https://supplierregistration.cabinetoffice.gov.uk - https://www.england.nhs.uk/ - https://www.england.nhs.uk// - https://www.judiciary.uk/courts-and-tribunals/high-court/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0445bc. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-0445bc.json.